Automated Systems for Detection and Molecular Characterization of Circulating Tum

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,086,427.00
Award Year:
2008
Program:
SBIR
Phase:
Phase II
Contract:
2R44CA122444-02A1
Award Id:
80042
Agency Tracking Number:
CA122444
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
6519 DUMBARTON CIR, FREMONT, CA, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
607435869
Principal Investigator:
() -
Business Contact:
() -
yluo@acdbio.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The detection and enumeration of circulating tumor cells (CTCs) has the potential to become a very powerful tool in cancer diagnosis and treatment. However, current technologies for CTC detection are not yet established in routine clinical practice. One reason is that CTCs are present in blood at an extremely low concentration of one in 10 million white blood cells. Existing technologies lack the sensitivity and/or specificity required for reliable detection of these rar e CTCs. Another reason is that current technology does not offer information about the molecular status of CTCs. The overall goal of this project is to develop an assay technology named QMAGEX for Quantitative Multiplex Analysis of Gene Expression in Singl e Cells and to utilize the technology for sensitive detection, accurate enumeration, and functional analysis of CTCs in body fluids. The long-term goal of this effort is to leverage this assay technology to develop a suite of high value cancer diagnostic p roducts. These products would satisfy many significant unmet needs in cancer diagnostics, especially in the area of early detection, therapy guidance and recurrence monitoring. In Phase I, we have developed a prototype QMAGEX assay, demonstrated its capabi lity for detecting RNA transcripts in situ in individual cells with single copy sensitivity, and proven its feasibility for cancer cell detection in blood. In Phase II, we aim to move QMAGEX from the current proof-of-concept stage to a robust and high info rmation content assay. The specific aims in Phase II include: 1) Develop essential components for high information content 4-plex QMAGEX assay; 2) Develop and validate a flow cytometric 4-plex QMAGEX assay for rare cell detection in blood; and 3) Evaluate the clinical utility of the high information content 4-plex QMAGEX assay for detection of CTCs in metastatic breast cancer patients. Commercial diagnostic products focusing on specific cancers and specific diagnostic applications will be developed in Phase III. PUBLIC HEALTH RELEVANCE: It has been known that circulating tumor cells (CTCs) can provide an early indication of tumor growth and metastasis. Thus, detection and molecular analysis of CTC using the QMAGEX assay system will be valuable in early detec tion of cancer, in identifying cancer patients for targeted therapies and determining response to treatment, in monitoring cancer progression and recurrence.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government